GNTA all -time high Jan 14, 1992 $170/share.
It had great potential back then with their drug
Genasense. Tesetaxel now looks like a winner!
Twenty-four patients are currently evaluable for response. Major objective responses (RECIST) have been observed in 50% of patients, including 1 complete response and 11 partial responses. Six of the 12 major responders have cleared more than 75% of their measurable disease. The disease control rate in this study, which includes major responders and patients with stable disease, is 83%.
Tesetaxel has been generally well-tolerated. The most common adverse effect (any grade) has been fatigue. Neutropenia has been the most common Grade 3-4 adverse event (52%); however, febrile neutropenia occurred in only 2 cases (6%). Consistent with prior studies, no hypersensitivity reactions were observed.
"These data confirm substantial activity for tesetaxel as initial chemotherapy for women with advanced, HER2-negative, breast cancer," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development, and Chief Medical Officer. "Based on aggregate data from our multicenter Phase 2 trials, we will be conferring with FDA to identify potential registration strategies for tesetaxel in breast cance
News 
Market Data 
Discover 
